These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19504188)

  • 1. Structure-activity relationships of tariquidar analogs as multidrug resistance modulators.
    Pajeva IK; Wiese M
    AAPS J; 2009 Sep; 11(3):435-44. PubMed ID: 19504188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators.
    Globisch C; Pajeva IK; Wiese M
    Bioorg Med Chem; 2006 Mar; 14(5):1588-98. PubMed ID: 16307883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
    Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
    Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar.
    Sun YL; Chen JJ; Kumar P; Chen K; Sodani K; Patel A; Chen YL; Chen SD; Jiang WQ; Chen ZS
    PLoS One; 2013; 8(2):e55576. PubMed ID: 23393594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions of the multidrug resistance modulators tariquidar and elacridar and their analogues with P-glycoprotein.
    Pajeva IK; Sterz K; Christlieb M; Steggemann K; Marighetti F; Wiese M
    ChemMedChem; 2013 Oct; 8(10):1701-13. PubMed ID: 23943604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure-Activity Relationships and Discovery of Promising MDR Reversal Agents.
    Zhu J; Wang R; Lou L; Li W; Tang G; Bu X; Yin S
    J Med Chem; 2016 Jul; 59(13):6353-69. PubMed ID: 27328029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
    Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
    Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
    Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
    J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
    Köhler SC; Wiese M
    J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of substituted 1,4-dihydroquinolines as novel promising class of P-glycoprotein inhibitors: First structure-activity relationships and bioanalytical studies.
    Hemmer M; Krawczyk S; Simon I; Hilgeroth A
    Bioorg Med Chem Lett; 2015 Aug; 25(15):3005-8. PubMed ID: 26048803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
    Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
    Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
    Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
    Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. pH sensitive liposomes delivering tariquidar and doxorubicin to overcome multidrug resistance of resistant ovarian cancer cells.
    Xia Y; Fang M; Dong J; Xu C; Liao Z; Ning P; Zeng Q
    Colloids Surf B Biointerfaces; 2018 Oct; 170():514-520. PubMed ID: 29960952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D-QSAR AND CONTOUR MAP ANALYSIS OF TARIQUIDAR ANALOGUES AS MULTIDRUG RESISTANCE PROTEIN-1 (MRP1) INHIBITORS.
    Kakarla P; Inupakutika M; Devireddy AR; Gunda SK; Willmon TM; Ranjana KC; Shrestha U; Ranaweera I; Hernandez AJ; Barr S; Varela MF
    Int J Pharm Sci Res; 2016 Feb; 7(2):554-572. PubMed ID: 26913287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Grid-independent Descriptors (GRIND) Analysis and SAR Guided Molecular Docking Studies to Probe Selectivity Profiles of Inhibitors of Multidrug Resistance Transporters ABCB1 and ABCG2.
    Shafi T; Jabeen I
    Curr Cancer Drug Targets; 2017; 17(2):177-190. PubMed ID: 27585695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators.
    Klinkhammer W; Müller H; Globisch C; Pajeva IK; Wiese M
    Bioorg Med Chem; 2009 Mar; 17(6):2524-35. PubMed ID: 19250834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.
    Fox E; Bates SE
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):447-59. PubMed ID: 17428165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tariquidar inhibits P-glycoprotein drug efflux but activates ATPase activity by blocking transition to an open conformation.
    Loo TW; Clarke DM
    Biochem Pharmacol; 2014 Dec; 92(4):558-66. PubMed ID: 25456855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the Binding Site of the Inhibitor Tariquidar That Stabilizes the First Transmembrane Domain of P-glycoprotein.
    Loo TW; Clarke DM
    J Biol Chem; 2015 Dec; 290(49):29389-401. PubMed ID: 26507655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR).
    Teodori E; Dei S; Martelli C; Scapecchi S; Gualtieri F
    Curr Drug Targets; 2006 Jul; 7(7):893-909. PubMed ID: 16842220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.